PEABODY, Mass., Oct. 14, 2025 /PRNewswire/ -- Privo Technologies, Inc. ("Privo" or "the Company"), a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果